Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7437779 | 0.81 | LMNA (0.66) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13055383 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL16404734 | 0.81 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL7378562 | 0.81 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL18732911 | 0.81 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL19145580 | 0.79 | SMN1; SMN2 (0.68) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL19750475 | 0.79 | LMNA (0.63) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL26630558 | 0.79 | LMNA (0.63) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8247523 | 0.79 | LMNA (0.63) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL966270 | 0.79 | LMNA (0.63) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | claimed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |